肿瘤间质成分在卵巢癌中的研究现状及进展

doi:10.3969/j.issn.1006-6233.2021.12.037

摘要
图/表
参考文献
相关文章 (13)

[1] Siegel R L,Miller K D,Jemal A.Cancer statistics,2020 [J].CA:a cancer journal for clinicians,2020,70(1):7~30.
[2] 徐蕾,黄骁昊,张智弘,戴辉华.选择性剪接在卵巢癌中的研究进展[J].临床与实验病理学杂志,2020,36(10):1198~1201.
[3] Rynne-vidal A,Au-yeung C L,Jimenez-heffernan J A,et al.Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer [J].The Journal of pathology,2017,242(2):140~151.
[4] Zhang Y,Tang H,Cai J,et al.Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis,lymphangiogenesis and tumor cell invasion [J].Cancer letters,2011,303(1):47~55.
[5] 李腾飞,黄陈.肿瘤间质成分在结直肠癌中的研究现状及进展[J].中华结直肠疾病电子杂志,2020,9(5):447~452.
[6] Clark R,Krishnan V,Schoof M,et al.Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models [J].The American journal of pathology,2013,183(2):576~591.
[7] Robinson-smith T M,Isaacsohn I,Mercer C A,et al.Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice [J].Cancer research,2007,67(12):5708~5716.
[8] Wang X,Zhu Q,Lin Y,et al.Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer [J].British journal of cancer,2017,117(9):1371~1382.
[9] Yang J,Wang Y,Zeng Z,et al.Smad4 deletion in blood vessel endothelial cells promotes ovarian cancer metastasis [J].International journal of oncology,2017,50(5):1693~1700.
[10] Nowicka A,Marini F C,Solley T N,et al.Human omental-derived adipose stem cells increase ovarian cancer proliferation,migration,and chemoresistance [J].PloS one,2013,8(12):e81859.
[11] Ghasemi A,Saeidi J,Azimi-nejad M,et al.Leptin-induced signaling pathways in cancer cell migration and invasion [J].Cellular oncology (Dordrecht),2019,42(3):243~260.
[12] Cubillos-ruiz J R,Silberman P C,Rutkowski M R,et al.ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis [J].Cell,2015,161(7):1527~1538.
[13] Vandam P A,Coelho A,Rolfo C.Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer? [J].European journal of surgical oncology :the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,2017,43(2):252~257.
[14] Ma R,Tang Z,Sun K,et al.Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival [J].Pathology,research and practice,2018,214(8):1115~1122.
[15] Zhu Q,Tang M,Wang X.The expression of asparaginyl endopeptidase promotes growth potential in epithelial ovarian cancer [J].Cancer biology & therapy,2017,18(4):222~228.
[16] Klymenko Y,Kim O,Loughran E,et al.Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis [J].Oncogene,2017,36(42):5840~5851.
[17] Li X,Tang M,Zhu Q,et al.The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration [J].Cellular oncology (Dordrecht),2020,43(2):263~277.